Scholars LITERATURE

Journal of Clinical Oncology and Therapeutics

Review Article

DOI: https://doi.org/10.47275/2690-5663-146
Volume 7 Issue 2

Cancer and Culture: Revolutionizing Breast and Cervical Cancer Strategies for Asian Women Using Artificial Intelligence

Ashmit Gupta[1*], Monish Thota[2], Rapelli Tejas Reddy[3*] and Samruddhi Mahesh Shende[4]

[1]SBKS Medical College and Research Centre, Vadodara, Gujarat, India
[2]Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, Telangana, India
[3]Shri B.M. Patil Medical College, Vijayapura, Karnataka, India
[4]Emilio Aguinaldo College, Philippines

Abstract

Breast and cervical cancers remain significant health challenges among Asian women, with distinct epidemiological patterns, cultural barriers, and disparities in healthcare access influencing outcomes. The need for targeted, population-specific approaches in screening, prevention, and treatment is critical, particularly as breast cancer incidence rises and cervical cancer continues to impose a heavy burden despite being largely preventable. This review explores the underlying factors contributing to these disparities, the role of artificial intelligence (AI) in advancing early detection and personalized treatment, and the necessity for culturally sensitive healthcare interventions. This review highlights key epidemiological trends, including the younger onset and more aggressive subtypes of breast cancer among Asian women, as well as the persistent challenges in cervical cancer screening and prevention. It discusses the impact of cultural stigmas, socioeconomic constraints, and healthcare infrastructure limitations on cancer outcomes. Furthermore, it examines the evolving role of AI in cancer diagnostics, risk assessment, and treatment planning. The review underscores the importance of integrating technological advancements with culturally tailored policies and healthcare strategies to improve screening rates, enhance treatment outcomes, and reduce cancer-related mortality among Asian women.

Keywords: Artificial intelligence, Asian women, Breast cancer, Cervical cancer, Healthcare accessibility, Personalized treatment, Screening disparities

***Correspondence to:** Ashmit Gupta and Rapelli Tejas Reddy, SBKS Medical College and Research Centre, Vadodara, Gujarat, India and Shri B.M. Patil Medical College, Vijayapura, Karnataka, India.

Citation: Gupta A, Thota M, Reddy RT, Shende SM (2025) Cancer and Culture: Revolutionizing Breast and Cervical Cancer Strategies for Asian Women Using Artificial Intelligence. J Clin Oncol Ther, Volume 7:2. 146. DOI: https://doi.org/10.47275/2690-5663-146

Received: April 01, 2025; **Accepted:** July 11, 2025; **Published:** July 17, 2025

Introduction

The heterogeneity in cancer screening behaviors and risk factors among Asian American subgroups highlights the need for targeted, culturally relevant interventions. Factors such as acculturation, education, health insurance, and access to care significantly influence screening rates [1-3]. Community-based programs using lay health workers, culturally tailored materials, and navigation assistance have shown promise in increasing screening rates and addressing disparities [4]. Furthermore, the effectiveness of polygenic risk scores developed for European-ancestry women in predicting breast cancer risk among Asian women suggests potential for risk-stratified screening programs in Asia [5].

Breast cancer incidence rates have been rising steadily in many Asian countries over the past few decades [6]. This trend is largely attributed to the rapid urbanization and widespread adoption of Western lifestyles, which often include changes in diet, physical activity levels, and reproductive patterns. The shift towards a more sedentary lifestyle, coupled with increased consumption of processed foods and alcohol, has contributed to higher obesity rates and hormonal imbalances, both of which are known risk factors for breast cancer [7, 8]. However, it is crucial to note that Asian women tend to develop breast cancer at a younger age compared to their Western counterparts. This earlier onset poses significant challenges for screening programs and early detection efforts. Additionally, Asian women are more likely to present with more aggressive subtypes of breast cancer, such as triple-negative breast cancer, which is associated with poorer prognosis and limited treatment options. These factors underscore the need for tailored screening guidelines and treatment protocols that account for the unique characteristics of breast cancer in Asian populations [9, 10].

Cervical cancer remains a significant health burden in many Asian nations, despite being largely preventable through human papillomavirus (HPV) vaccination and regular screening programs [11, 12]. The high incidence and mortality rates associated with cervical cancer in Asian countries are particularly concerning, given that effective prevention and early detection methods are available [13]. However, several factors contribute to the persistence of this preventable disease in Asian populations. One of the primary challenges in addressing cervical cancer in Asian women is limited healthcare access, particularly in rural and underserved areas [14, 15]. Many women lack access to regular gynecological care, HPV vaccination, and cervical cancer screening services. This lack of access is often compounded by financial barriers, as many women may not have the means to afford preventive care or cancer treatment [16, 17]. Cultural barriers also play a significant role in the high cervical cancer burden among Asian women.

In many Asian cultures, there is a stigma associated with discussing reproductive health issues, which can lead to reluctance in seeking medical care or participating in screening programs [18]. Additionally, traditional beliefs and practices may sometimes conflict with modern medical approaches, further complicating efforts to implement effective prevention and treatment strategies [19, 20]. Lack of awareness about cervical cancer, its causes, and prevention methods is another critical factor contributing to the high disease burden [21]. Many women may not understand the importance of regular screening or the link between HPV and cervical cancer. This knowledge gap can result in delayed diagnosis and poorer outcomes, as women may not recognize early symptoms or seek medical attention until the disease has progressed to more advanced stages.

Epidemiology of Breast and Cervical Cancer

Oncology in Asian women, particularly concerning cervical and breast cancers, presents unique challenges and considerations that require careful attention from healthcare professionals and policymakers [22, 23]. These two types of cancer have significant impacts on the health and well-being of Asian women, with distinct patterns and risk factors that differ from those observed in Western populations (Table 1) [24, 25]. Cervical and breast cancer screening rates among Asian American women show significant variation across different nationalities and subgroups. While overall mammography rates increased from 75.6% in 2001 to 81.8% in 2009, Papanicolaou test rates remained relatively stable at around 80% [1]. However, striking disparities exist, with Vietnamese women having the highest cervical cancer incidence (18.9 per 100,000) and Asian Indian/Pakistani women the lowest (4.5 per 100,000) [26]. Interestingly, contrary to the plateau observed in white women, cervical squamous cell carcinoma (SCC) rates continued to rise with age among Chinese, Filipina, Korean, and Vietnamese women [26]. Additionally, while Asian women generally have denser breasts than Western women, their breast cancer incidence is lower. However, the risk of breast cancer still increases with breast density measured using the percent density index, regardless of menopausal status [27].

Breast cancer is the most commonly diagnosed cancer among women globally, and its incidence is rising in many Asian countries. For instance, a study examining breast cancer among Asian Indian and Pakistani American women found that they are diagnosed at a significantly younger age compared to non-Hispanic white women, with a mean age of 54.5 years vs 62 years, respectively [28]. Furthermore, Asian women often present with more aggressive tumor characteristics, such as higher rates of triple-negative and HER2-positive breast cancers [29]. In a systematic review, it was noted that family history significantly increases breast cancer risk among Asian women, with a pooled odds ratio of 2.46 for those with a first-degree relative diagnosed with the disease [30]. This familial risk is comparable to that observed in women of European ancestry, suggesting that genetic factors play a substantial role in breast cancer susceptibility across different ethnicities.

A study explored the differences in breast cancer presentation, recurrence, and survival among young women of various race/ethnic backgrounds [31]. The research included 240 women aged 40 years and younger with a new diagnosis of breast cancer, who were referred to the Sunnybrook Odette Cancer Center between February 2008 and January 2015. Out of these, 209 women (87%) had known parental race/ethnicity and were not of mixed ancestry. The racial/ethnic breakdown was as follows: Caucasian: 57.4% (n = 120); Black: 8.6% (n = 18); East Asian: 15.8% (n = 33); South Asian: 8.6% (n = 18); and South-East Asian: 9.6% (n = 20). The median age at diagnosis was 37 years, with a median tumor size of 2.5 cm. Notably, 58% of the patients had lymph node involvement. The majority of the tumors were hormone receptor-positive/HER2-negative, while 26% were HER2-positive, and 13% were triple-negative breast cancer. A significant portion of the patients (83.7%) received chemotherapy, with 29.1% undergoing treatment in the neoadjuvant setting. There were no statistically significant differences in treatment across the various racial/ethnic groups. With a median follow-up of 10.5 years, the study found that: South Asian women had a non-significantly higher risk of distant recurrence (Hazard ratio (HR) = 1.27, p = 0.627) and breast cancer-specific death (HR = 1.42, p = 0.521) compared to Caucasian women. East Asian women exhibited the lowest risk of distant recurrence (HR = 0.52, p = 0.224) and breast cancer-related death (HR = 0.36, p = 0.167). The findings suggest trends indicating worse breast cancer outcomes among South Asian women and better outcomes among East Asian women. The authors recommend further validation of these results in

Table 1: Epidemiological overview of breast and cervical cancer: risk factors, screening, and outcomes.

Factor	Breast cancer	Cervical cancer
Incidence	Most common cancer in women worldwide	Fourth most common cancer in women worldwide
Mortality rate	High but improving due to early detection and treatment	Significant, especially in low-income countries
Age group affected	Most common in women aged 50+ but can occur earlier	Most common in women aged 30 - 50
Major risk factors	Age, genetics (BRCA1/BRCA2 mutations), hormonal factors, obesity, alcohol consumption, late/no childbirth, hormone therapy	HPV infection (high-risk types 16, 18), smoking, multiple sexual partners, early sexual activity, immunosuppression
Prevention	Lifestyle modifications, regular mammography screening, chemoprevention (e.g., tamoxifen) for high-risk groups	HPV vaccination, regular Pap smear and HPV testing, safe sexual practices
Screening methods	Mammography, breast self-exam, clinical breast exam, MRI for high-risk individuals	Pap smear, HPV DNA test, visual inspection with acetic acid in low-resource settings
Global burden	High incidence in both developed and developing countries	Higher burden in low- and middle-income countries due to lack of screening
Primary treatment	Surgery (lumpectomy/mastectomy), chemotherapy, radiation therapy, hormonal therapy (Tamoxifen, Aromatase inhibitors), targeted therapy (HER2 inhibitors)	Surgery (LEEP, hysterectomy), radiotherapy, chemotherapy, targeted therapy in advanced cases
Survival rate	5-year survival rate > 90% in early-stage cases	5-year survival rate varies widely; high in early stages (>90%) but low in advanced stages
Public health impact	Major focus of cancer awareness programs; pink ribbon campaigns	Increasing focus on HPV vaccination and cervical cancer screening programs

a larger cohort of young women with breast cancer to confirm these observations [31].

Cervical cancer remains a leading cause of cancer morbidity and mortality among women in Asia. Data from Indonesia indicated that cervical cancer accounted for 15.8% of all cancer cases, highlighting its prevalence in the region [32]. Additionally, a systematic literature review revealed that the proportion of women with locally advanced cervical cancer (LACC) is notably high in Asia, with estimates reaching up to 50% in some studies [33]. The awareness of cervical cancer risk factors and symptoms is crucial for early detection and treatment. A study conducted in Uganda and South Africa found that while awareness of cervical cancer symptoms was relatively high, many women were unaware of significant risk factors such as HPV and HIV [34]. This gap in knowledge underscores the need for targeted educational interventions to improve screening rates and early diagnosis.

The trends in breast and cervical cancer incidence in Asia show a concerning increase. An ecological study covering the period from 1998 - 2012 found that breast cancer incidence rates have been steadily rising, with an average annual percentage change of 2.1% [35]. In contrast, cervical cancer incidence rates displayed a declining trend, which may reflect improvements in screening and vaccination efforts against HPV [35]. In Japan, while the overall cancer mortality rate is decreasing, the mortality rates for breast and cervical cancers have not followed this trend, indicating a need for enhanced screening and prevention strategies [36]. The disparities in cancer outcomes among different Asian populations highlight the importance of culturally sensitive healthcare approaches that consider socioeconomic factors and access to medical services.

Barriers to timely screening and care for breast and cervical cancers are prevalent in many Asian communities. A study in Uganda and South Africa identified financial constraints as a significant barrier, with many women anticipating difficulties in accessing healthcare due to transport costs [37]. Similarly, limited English proficiency among Asian American populations has been associated with lower rates of cancer screening, emphasizing the need for language-appropriate healthcare services [38]. Efforts to improve cancer screening rates must address these barriers by enhancing community awareness, providing financial assistance, and ensuring that healthcare providers are culturally competent and sensitive to the needs of diverse populations.

The epidemiology of breast and cervical cancer in Asian women reveals critical insights into the rising incidence and unique characteristics of these diseases. Addressing the disparities in awareness, access to care, and screening practices is essential for improving outcomes. Future research should focus on disaggregating data by specific ethnic groups to better understand the nuances of cancer epidemiology in Asia and to inform targeted interventions that can effectively reduce the burden of these cancers.

Impact of Cultural Factors on Cancer Screening

Cultural factors significantly impact cancer screening behaviors among Asian American women, with notable variations across different nationalities and subgroups (Table 2). Asian American women generally have lower rates of breast and cervical cancer screening compared to non-Hispanic White women [39, 40]. However, there is considerable heterogeneity within Asian American subgroups. For instance, Filipino American women have the highest Pap test rates (81%), while Vietnamese American women have the lowest (61%) [39]. Similarly, for mammography, Japanese American women have the highest rates (78%), while Korean American women have the lowest (53%) [39].

Cultural beliefs and attitudes play a crucial role in these disparities. Eastern cultural views, such as beliefs in the role of luck and self-care, are associated with lower screening rates [40]. Additionally, factors like immigration stress, acculturation level, English proficiency, social support, and spirituality influence health behaviors and health-related quality of life among Asian American breast cancer patients [41]. Cultural and linguistic barriers also contribute to unmet physical and emotional needs during cancer survivorship [41]. Understanding the cultural nuances of each Asian American subgroup is essential for developing effective cancer screening interventions. Successful programs should incorporate culturally tailored and linguistically appropriate educational materials, use community individuals as lay health workers, and provide navigation assistance to overcome access barriers [4]. Future research should focus on disaggregating data for different Asian American subgroups and exploring the interplay between cultural factors and cancer screening behaviors to develop targeted, culturally sensitive interventions [42, 43].

Culturally tailored interventions, community health workers (CHWs), and navigation assistance have shown promise in overcoming barriers to cancer screening among diverse Asian American subgroups. Culturally tailored interventions that address language barriers, cultural beliefs, and health literacy have been effective in increasing cancer screening rates among Asian American populations [4, 44]. These interventions often utilize culturally relevant materials and provide information in the target population's native language [44].

Table 2: Cultural barriers influencing cancer screening among Asian women.

Cultural factor	Impact on cancer screening	Affected cancer types
Modesty and privacy concerns	Reluctance to undergo screenings like mammograms and Pap smears due to embarrassment or discomfort with male healthcare providers	Breast and cervical
Traditional beliefs and fatalism	Belief that cancer is a death sentence, leading to fear and avoidance of screening	Breast, cervical, and ovarian
Family and social influence	Decision-making often influenced by family members, particularly male relatives, leading to delays in seeking preventive care	Breast and cervical
Stigma around cancer	Fear of social ostracization, especially regarding reproductive cancers, discouraging open discussions and screenings	Cervical and ovarian
Religious and cultural taboos	Restrictions on discussing female health issues or undergoing medical procedures perceived as invasive	Breast and cervical
Limited health literacy	Lack of awareness about the importance of early detection and available screening programs	Breast, cervical, and colorectal
Preference for traditional medicine	Some women prioritize herbal or alternative treatments over medical screenings and interventions	Breast and cervical
Financial barriers and accessibility	High costs of screening and limited availability of female healthcare providers deter participation	Breast and cervical
Migrant and minority status	Language barriers and lack of trust in the healthcare system reduce screening rates among immigrant populations	Breast, cervical, and liver
Work and family responsibilities	Women prioritize family and work obligations over their own health, leading to missed screening opportunities	Breast and cervical

For instance, a pilot Cancer Screening Education Program developed for various culturally and linguistically diverse communities, including Vietnamese and South Asian groups, demonstrated improvements in knowledge, attitudes, and intentions to participate in cancer screening [45]. CHWs play a crucial role in these interventions by increasing cancer awareness, knowledge, and encouraging screening [44]. CHWs from the same cultural background can build trusting relationships with community members and address cultural, historical, and structural needs [46].

A study on training South Asian women as CHWs showed promising results in improving their knowledge, self-efficacy, and competence in promoting cancer prevention awareness among their peers [47]. Navigation assistance has been particularly effective in overcoming access barriers and improving screening rates [4, 48]. For example, a culturally tailored, language-concordant navigator program significantly improved colonoscopy rates for low-income, ethnically diverse patients [48]. Similarly, a mobile app intervention combined with health navigation services was found to be feasible and effective in promoting breast cancer screening behaviors among Korean American immigrant women [49]. A combination of culturally tailored interventions, CHWs, and navigation assistance can effectively address the multiple barriers faced by Asian American subgroups in accessing cancer screening services. These approaches help overcome language barriers, cultural beliefs, lack of knowledge, and access issues, ultimately leading to improved cancer screening rates and health outcomes for these diverse communities [4, 44, 50].

Treatment Strategies for Breast and Cervical Cancer

Treatment strategies for breast and cervical cancer have evolved significantly over the years, focusing on personalized approaches that combine surgery, radiation, chemotherapy, and targeted therapies [51]. For breast cancer, treatment often involves a combination of surgery (lumpectomy or mastectomy), chemotherapy, radiation, hormone therapy, and newer options like targeted therapies (e.g., HER2 inhibitors) and immunotherapy, tailored to the cancer's type and stage [52]. In contrast, cervical cancer treatment primarily relies on surgery (e.g., hysterectomy or cone biopsy), radiation, and chemotherapy, with the option of targeted therapies for advanced cases. Advances in early detection and screening have also improved treatment outcomes for both cancers, with increasing emphasis on prevention through vaccination (HPV for cervical cancer) and lifestyle modifications [53, 54]. The goal is to provide individualized treatment plans that maximize survival while minimizing side effects, aiming for a holistic approach to patient care.

Breast cancer

Breast cancer treatment strategies have evolved significantly, incorporating a range of approaches tailored to the type and stage of the disease (Figure 1). These strategies include traditional methods such as surgery, chemotherapy, and radiation, as well as innovative techniques like targeted therapy, immunotherapy, and advanced drug delivery systems [55]. The integration of these methods aims to improve treatment efficacy, reduce side effects, and enhance patient quality of life. Below, key aspects of breast cancer treatment strategies are discussed, highlighting both conventional and emerging approaches.

Conventional treatment methods

- Surgery: Surgical options include lumpectomy and mastectomy, often followed by radiation therapy to eliminate residual cancer cells. Minimally invasive surgery is gaining popularity due to its reduced physical and psychological impact, offering faster recovery and better cosmetic outcomes [56].

- Chemotherapy and radiation: These remain standard treatments, particularly for advanced stages. Chemotherapy uses cytotoxic drugs to target rapidly dividing cells, while radiation therapy focuses on destroying cancer cells in specific areas [57, 58].

- Hormonal therapy: Used for hormone receptor-positive breast cancers, hormonal therapies aim to block or lower estrogen levels, slowing the growth of tumors [58, 59].

Emerging and innovative strategies

- Combination chemotherapy: This approach uses multiple drugs to target cancer through different mechanisms, often incorporating phytoconstituents to enhance efficacy and reduce resistance [60].

- Nanotechnology and drug delivery systems: Nanoparticles and other nanocarriers are being developed to improve drug delivery,



Figure 1: Different strategies to treat different types of breast cancer [55].

targeting cancer cells more precisely and minimizing damage to healthy tissues. These systems include liposomes, dendrimers, and polymeric micelles [60, 61].

- Immunotherapy: Strategies to convert "cold" tumors into "hot" tumors involve using nanoparticles to modify the tumor microenvironment, enhancing immune cell infiltration and activation [62].

- Gene therapy and targeted therapy: These therapies focus on specific genetic and molecular pathways involved in cancer progression, offering personalized treatment options based on individual patient profiles [58].

Treatment for specific conditions

- Fungating and ulcerating tumors: These complex cases require a combination of local and systemic treatments. Surgical intervention, radiotherapy, and chemotherapy are tailored based on tumor characteristics and patient demographics [63].

- Stage-specific treatments: Early-stage breast cancer may benefit from less invasive treatments like minimally invasive surgery, while advanced stages often require a combination of systemic therapies to manage symptoms and prolong life [56, 59].

While these strategies represent significant advancements in breast cancer treatment, challenges remain, particularly in addressing drug resistance and ensuring equitable access to care. The integration of lifestyle modifications and preventive measures, such as reducing alcohol intake and maintaining a healthy weight, also plays a crucial role in managing breast cancer risk [64]. As research continues, the focus on personalized medicine and innovative technologies promises to further enhance treatment outcomes and patient quality of life.

Cervical cancer

Cervical cancer treatment strategies have evolved significantly, incorporating a range of modalities from traditional methods to cutting-edge therapies (Figure 2). These strategies aim to improve patient outcomes, manage advanced stages, and address quality of life concerns. The integration of surgical advancements, chemotherapy, radiation, immunotherapy, and novel drug delivery systems represents a comprehensive approach to managing cervical cancer. Below, the key treatment strategies are discussed in detail.



Figure 2: Different strategies to treat cervical cancer [65].

Surgical and conventional therapies

- Surgical techniques: Radical hysterectomy and minimally invasive procedures are standard surgical options, with advancements enhancing patient outcomes and quality of life. For early-stage cervical cancer, fertility-preserving surgeries like trachelectomy are viable options [66, 67].

- Chemotherapy and radiation: These remain vital components, especially for LACC. New drug regimens and combination therapies have improved efficacy and tolerance. Radiation therapy techniques have been refined to maximize tumor control while minimizing adverse effects [66, 68, 69].

Immunotherapy and targeted therapies

- Immune checkpoint inhibitors: Immune checkpoint inhibitors, such as anti-PD-1, have shown promising results in LACC by enhancing anti-tumor immune responses. Adoptive T cell therapy and therapeutic vaccines targeting HPV antigens are also under investigation (Figure 3) [71].

- Targeted therapies: These focus on specific biochemical pathways, offering personalized treatment approaches. They are particularly beneficial in cases where conventional therapies are less effective [66, 72].

Novel drug delivery systems

- Localized treatment approaches: Novel carriers like nanofibers, nanoparticles, and hydrogels are being developed to deliver therapeutics directly to the tumor site, reducing systemic toxicity and improving efficacy. These systems are designed to maintain therapeutic levels locally for extended periods [73].

- Nanocarriers: These offer a promising approach for concurrent chemotherapeutic drug delivery, potentially overcoming the limitations of traditional chemotherapy [74].

Advanced imaging and treatment planning

- [18F]FDG-PET/CT: This imaging technique is crucial for staging and treatment planning in LACC, guiding interventions such as nodal boosting and extended-field radiotherapy. However, the risk of false positives necessitates careful interpretation [75].

- Magnetic resonance imaging (MRI)-guided adaptive beam therapy: This modern radiation therapy method allows for precise targeting of metastatic pelvic lymph nodes (PLN), improving treatment outcomes while reducing treatment times [69].

Fertility preservation and quality-of-life

- Fertility-sparing options: For women diagnosed during reproductive years, options like trachelectomy and ovarian transposition are available. These strategies aim to preserve fertility while maintaining oncologic safety [67].

- Quality-of-life considerations: Addressing the financial toxicity and disparities in treatment access is crucial. Ensuring equitable access to HPV vaccination, screening, and treatment is essential for improving outcomes globally [72].

While these strategies represent significant advancements in cervical cancer treatment, challenges remain, particularly in ensuring equitable access to these therapies across different regions. The integration of novel therapies with traditional methods offers hope for



Figure 3: Schematic overview of cancer immunotherapies to target cervical cancer [70].

improved outcomes, but ongoing research and evidence-based care are necessary to address the unmet needs in cervical cancer management.

Clinical Studies Focusing on Treatment Strategies

Breast and cervical cancers are significant health concerns for women in Asia, with varying treatment strategies influenced by cultural, economic, and healthcare system factors. This section explores the treatment approaches for these cancers, highlighting recent advancements and challenges faced by Asian women.

Breast Cancer Treatment

Breast cancer is a leading cause of cancer-related deaths worldwide, and its treatment strategies vary significantly across different populations due to genetic, environmental, and socioeconomic factors. In Asian women, breast cancer treatment strategies have been studied extensively, revealing unique challenges and opportunities.

A study included a total of 160 patients, with 116 presenting with symptomatic breast cancer, primarily characterized by a palpable mass [76]. Most of these patients (92.2%) were of Asian ethnicity, with 69% being Chinese. The average age at diagnosis was 48.3 years, and the mean tumor size was 23.4 mm. Out of the 116 patients with symptomatic breast cancer, 95 (81.9%) underwent breast conservation treatment (BCT). This indicates a significant utilization of BCT among the study population, which is higher than the reported rates in other studies. Among the 22 patients who were initially assessed to have tumors too large for direct surgery, 13 (59%) were able to successfully undergo BCT after receiving neoadjuvant chemotherapy that down staged their tumors. The study found that while 95 patients were eligible for BCT, eight chose mastectomy instead. If these patients had opted for BCT, the overall BCT rate could have reached 88.8%. The follow-up period averaged 91.4 months, with a 5-year overall survival rate of 97.4% for patients with symptomatic lesions. The disease-free survival rate was 94%. The results also indicated that BCT did not compromise survival outcomes. The 5-year overall survival for women who underwent BCT was 97.7%, compared to 95.2% for those who had mastectomy, although this difference was not statistically significant. The study concluded that it is feasible for a majority of Asian women with symptomatic breast malignancies to undergo BCT, suggesting that with appropriate medical therapy and surgical techniques, BCT rates could be optimized to at least 80%. These findings highlight the potential for improving BCT utilization in Asian populations, which is crucial given the associated survival benefits [76].

Another study analyzed the medical records of 2,492 Asian breast cancer patients who underwent BCT between 1989 and 2012 [77]. It aimed to understand how age affects locoregional recurrence and survival rates in these patients. Patients aged 40 years or younger had a significantly higher likelihood of locoregional recurrence compared to older patients, with a HR of 2.32, indicating they were more than twice as likely to experience this issue. The rates of locoregional recurrence decreased annually by 4% for patients with luminal-type breast cancers and by 8% for those with triple-negative cancers. This suggests that younger patients face more aggressive forms of cancer. Breast cancer-free survival rates also improved year-on-year, with increases of 4% for luminal-type cancers and 8% for triple-negative cancers. This indicates that younger patients have a higher risk of recurrence. The study found that breast cancer-specific survival rates increased with age, with a 5% annual increase. This means that older patients generally had better survival outcomes compared to younger patients. The relationship between age and breast cancer outcomes was complex. For younger patients, there was a continuous increase in the risk of relapse and death without a clear threshold age. This contrasts with older patients, where the influence of age on overall survival was affected by other health issues unrelated to cancer. The findings highlighted that young Asian breast cancer patients treated with BCT have higher rates of local recurrence and breast cancer-related deaths compared to older patients. This emphasizes the need for tailored treatment approaches for younger patients. Overall, the study concluded that every year of increased age at diagnosis improved local control and reduced breast cancer mortality, indicating that age is a significant factor in breast cancer outcomes [77].

A study presents significant findings regarding the efficacy and toxicity of cyclin D kinase 4/6 (CDK4/6) inhibitors in advanced breast cancer, particularly focusing on the impact of ethnicity [78]. The addition of CDK4/6 inhibitors to endocrine therapy significantly improves progression-free survival (PFS) in patients with advanced breast cancer. The overall HR for PFS when comparing CDK4/6 inhibitor-endocrine therapy to endocrine monotherapy was 0.56 (95% CI 0.50 - 0.62), indicating a substantial benefit from the combination therapy. The analysis revealed that the efficacy of the treatment varies by ethnicity: In Asian patients (n = 492), the PFS HR was notably lower at 0.39 (95% CI 0.29 - 0.51, p < 0.0001), suggesting a greater benefit from the combination therapy. In non-Asian patients (n = 2007), the PFS HR was 0.62 (95% CI 0.54 - 0.71, p < 0.0001), indicating a lesser but still significant benefit compared to the Asian subgroup. The study found a significant interaction between treatment efficacy and ethnicity (p = 0.002), highlighting that the benefit of adding CDK4/6 inhibitors to endocrine therapy is more pronounced in Asian patients compared to non-Asians. Toxicity data were available from only two trials (n = 1334), and the results did not provide convincing evidence of differences in treatment-related toxicities between the ethnic groups. This suggests that while efficacy may vary by ethnicity, the relative risk of toxicity does not. The findings emphasize the need for further research into the pharmacogenomics of CDK4/6 inhibitors and their varying effects across different ethnic groups. This could inform trial designs and economic analyses in the future. In summary, the study concludes that while CDK4/6 inhibitors significantly enhance PFS in advanced breast cancer, the degree of benefit is influenced by ethnicity, with no significant differences in toxicity observed [78].

A study involved 1542 early breast cancer patients from the Asia-Pacific region who received docetaxel-based adjuvant therapy between 2006 and 2013 [79]. The patients were followed for 5 years to assess safety, relapse, and survival outcomes. Among the patients, 92% received anthracycline-containing regimens, while 8% received non-anthracycline-containing docetaxel-based regimens. The mean dose intensity of docetaxel varied across treatment types, with values of 25.8 mg/m^2/week for monotherapy, 22.4 mg/m^2/week for combination therapy, and 25.4 mg/m^2/week for sequential therapy. Adverse events were reported in 94.9% of patients, with serious adverse events occurring in 12.6%. The most common AEs included alopecia, nausea, neutropenia, and vomiting. Grade 4 neutropenia was reported in 25.2% of patients. At the 5-year follow-up, 127 patients (8.3%) had died, and only 7% experienced a relapse or a second primary malignancy. The study found that 70.5% of patients were alive without relapse or second malignancy. The disease-free survival rate was 82%, and the overall survival rate was 91% at the end of the 5-year follow-up. The median disease-free survival was approximately 1827 days, while the median overall survival was around 1824 days. The study highlighted significant differences in disease-free survival and overall survival rates among different countries in the Asia-Pacific region, which may be attributed to variations in treatment regimens and patient populations. Overall, the findings suggest that docetaxel-based adjuvant therapy is effective for early breast cancer patients in the Asia-Pacific region, with comparable safety and survival outcomes to those reported in other studies [79].

Cervical Cancer Treatment

Cervical cancer remains a significant health burden in Asian countries, with varying treatment strategies and outcomes. This section summarized findings from multiple clinical studies to provide insights into treatment strategies, prognostic factors, and quality of life outcomes for cervical cancer in Asian women.

A study reviewed the treatment outcomes of 135 patients with LACC who underwent computed tomography (CT)-guided brachytherapy at Queen Mary Hospital, Hong Kong, between November 2013 and December 2019 [80]. The median follow-up period for these patients was 53.6 months, with a range from 3.0 to 99.6 months. The five-year local control rate was 90.7%, meaning that most patients did not have cancer recurrence in the treatment area. The five-year pelvic control rate was 84.3%, indicating that the cancer did not spread to the pelvic region in most patients. The five-year distant metastasis-free survival rate was 80.0%, which means that 80% of patients did not develop cancer in other parts of the body. The overall survival rate after five years was 87.2%, showing that a significant majority of patients were still alive. However, the study found that patients with adenocarcinoma had worse outcomes compared to those with SCC. The five-year local control rate for adenocarcinoma was only 74.8%, compared to 95.1% for SCC. Similarly, the five-year pelvic control rate was 63.9% for adenocarcinoma vs 89.7% for SCC. The overall survival rate was also lower for adenocarcinoma patients, at 69.3% compared to 92.7% for SCC patients. The study reported that 11.9% of patients experienced long-term complications after treatment, with 6.7% having severe complications (grade 3 or above). Overall, the findings suggest that CT-guided brachytherapy is an effective treatment for LACC, but patients with adenocarcinoma may require more tailored treatment strategies due to their poorer prognosis [80].

A study presented significant findings regarding the use of pembrolizumab in combination with chemoradiotherapy for patients with high-risk, LACC in Aisa [81]. This was a randomized, phase III, double-blind study (ENGOT-cx11/GOG-3047/KEYNOTE-A18) that compared pembrolizumab (pembro) plus concurrent chemoradiotherapy (CCRT) against placebo (pbo) plus CCRT in patients with high-risk LACC. A total of 299 patients were enrolled from East Asia, including countries like China, Japan, South Korea, Thailand, and Taiwan. Patients were randomly assigned to receive either pembro + CCRT (n = 153) or pbo + CCRT (n = 146). The median PFS was not reached in either treatment group. However, the HR for PFS was 0.55 (95% CI, 0.35 - 0.88), indicating a significant improvement in PFS for the pembrolizumab group. The 24-month PFS rate was 77.6% for the pembro + CCRT group compared to 59.8% for the pbo + CCRT group. While the median overall survival was also not reached in either group, there was a favorable trend for improved overall survival in the pembrolizumab group, with an HR of 0.73 (95% CI, 0.49 - 1.07). Grade ≥3 treatment-related adverse events occurred in 78.3% of patients receiving pembro + CCRT and 77.4% in the pbo + CCRT group, with no grade 5 events reported. Immune-mediated adverse events were observed in 43.4% of the pembrolizumab group compared to 10.3% in the placebo group. The results suggest that pembrolizumab combined with CCRT may be a new treatment option for patients with high-risk LACC in East Asia, demonstrating a PFS benefit with manageable safety. These findings highlight the potential of pembrolizumab as an effective treatment strategy in this patient population [81].

A study analyzed 192 patients with LACC who were treated with CCRT at Xiangya Hospital from January 2014 to June 2017 [82]. The patients were in stages IIB to IVA according to the FIGO staging system. The median follow-up time for these patients was 39.5 months. During this period, 33 patients (17.2%) experienced tumor recurrence or metastasis, and 21 patients (10.9%) died. The three-year overall survival rate was reported to be 89.1%, while the three-year PFS rate was 82.8% for all patients. The study found that patients with non-SCC (NSCC), which includes adenocarcinoma and adenosquamous carcinoma, had significantly lower survival rates compared to those with SCC. Specifically, the overall survival rates were 91.6% for SCC vs 57.1% for NSCC, and PFS rates were 86.0% for SCC vs 42.9% for NSCC. Advanced disease stages (IIIA-IVA) were associated with poorer survival outcomes. Patients in these advanced stages had worse overall survival and PFS compared to those in stage IIB. The presence of positive PLN and para-aortic lymph nodes (PALN) also negatively impacted survival rates. For instance, the overall survival rates for patients with negative vs positive PLN were 94.2% vs 82.6%, and for PALN, they were 91.6% vs 57.1%. A lower pretreatment hemoglobin (HGB) level (< 126 g/L) was identified as an independent prognostic factor for PFS. Patients with lower HGB levels had worse survival outcomes, with overall survival rates of 93.3% vs 84.1% for those with HGB levels ≥ 126 g/L. The study concluded that NSCC and PALN metastasis are significant poor prognostic factors for both overall survival and PFS in LACC patients treated with CCRT, while lower pretreatment HGB levels are an independent factor affecting PFS [82].

A study aimed to assess the quality-of-life outcomes in women who underwent different treatment approaches for cervical cancer [83]. The study involved 131 cervical cancer patients and compared quality-of-life outcomes among three treatment approaches: (1) Chemotherapy, radiotherapy, and brachytherapy, (2) Isolated hysterectomy, and (3) Hysterectomy combined with radiotherapy. Patients who underwent the chemo/radio/brachytherapy treatment reported significantly lower quality-of-life scores compared to those who had isolated hysterectomy. This was particularly evident in the FACIT-Cx subscales, which measure physical well-being and specific concerns, as well as the overall FACIT-total score ($p < 0.05$). The MDASI (MD Anderson Symptom Inventory) results indicated that patients in the chemo/radio/brachytherapy group experienced greater symptoms and more interference in their daily activities compared to those who had isolated hysterectomy. The study highlighted the need to address sexual concerns in quality-of-life assessments for cervical cancer survivors, as these factors are often underestimated due to societal taboos. This underscores the importance of comprehensive care that includes discussions about sexual health. The findings suggest that isolated hysterectomy leads to better quality-of-life outcomes compared to more aggressive treatments like chemo/radio/brachytherapy. The study emphasizes the necessity of considering sexual health and overall well-being in post-treatment care for cervical cancer patients. In summary, the study provides valuable insights into how different treatment approaches for cervical cancer impact the quality-of-life, particularly emphasizing the advantages of isolated hysterectomy and the need for holistic care that includes sexual health considerations [83].

Role of AI

AI plays a transformative role in the detection, diagnosis, and management of breast and cervical cancer. By leveraging machine learning and deep learning techniques, AI enhances the precision and efficiency of cancer screening and diagnosis (Figure 4), which is crucial for improving patient outcomes [85, 86]. AI systems are particularly beneficial in regions with limited access to healthcare resources, as they can provide consistent and accurate diagnostic support (Table 3). The following sections detail the specific roles AI plays in breast and cervical cancer care.

In breast cancer

AI is increasingly recognized as a transformative tool in the detection, diagnosis, and treatment of breast cancer. The integration of AI into breast cancer care has shown potential in enhancing diagnostic accuracy, improving treatment planning, and ultimately, patient outcomes. This section explores the various applications of AI in breast cancer care, highlighting its benefits and the challenges that need to be addressed for its broader adoption.

In detection

- Enhanced imaging techniques: AI has significantly improved the sensitivity and specificity of breast cancer detection, particularly in imaging modalities like mammography, MRI, and ultrasound. AI models, such as Faster R-CNN, have demonstrated superior performance in detecting small lesions, reducing false positives, and assisting radiologists in early cancer detection [87, 88].



Figure 4: Role of AI in cancer, including early screening, diagnosis, treatment, prognosis, and clinical decision-making [84].

Table 3: Overview of role of AI in cancer detection, diagnosis, and treatment.

Focus area	Role of AI
Early detection	• AI algorithms analyze medical imaging (e.g., mammograms, CT scans, MRIs) to detect early signs of cancer, improving accuracy and speed • AI-based screening tools help identify high-risk patients for earlier intervention
Diagnosis	• AI models assist pathologists in analyzing tissue samples, biopsies, and pathology slides to identify cancerous cells • AI aids in diagnosing specific cancer types (e.g., breast, prostate) through pattern recognition in imaging and genetic data
Personalized treatment	• AI algorithms analyze patient data (genetic, clinical, imaging) to recommend personalized treatment plans • AI-based models predict the response to treatments like chemotherapy, immunotherapy, or targeted therapy
Drug development	• AI accelerates the discovery of new cancer drugs by predicting molecular behavior and identifying potential therapeutic compounds • Machine learning models are used to optimize drug screening processes and clinical trial design
Radiotherapy	• AI helps plan precise radiation treatment by analyzing imaging data and optimizing radiation delivery to tumors while minimizing damage to healthy tissues
Clinical decision support	• AI assists oncologists by providing evidence-based recommendations, treatment guidelines, and identifying potential complications
Predicting recurrence	• AI models predict the likelihood of cancer recurrence using patient data such as genetic mutations, imaging, and clinical history
Monitoring treatment response	• AI tools analyze changes in tumor size, shape, and biomarkers over time, helping to track treatment efficacy
Genomics and precision medicine	• AI plays a significant role in analyzing large genomic datasets to identify mutations, biomarkers, and targeted treatments
AI-assisted surgery	• AI helps surgeons with precision in planning and executing cancer surgeries, especially in complex cases
Chatbots and virtual assistants	• AI-driven chatbots provide patients with support, information about treatments, and reminders for follow-up care and medication
Medical imaging analysis	• AI-powered software interprets imaging scans (e.g., CT, MRI, and PET) more quickly and accurately, often detecting subtle signs of cancer that human eyes might miss

- Automated classification: Machine learning models, including AutoML - TPOT with PCA, have achieved high accuracy rates in classifying breast cancer, with some models reaching up to 98.6% accuracy. These models enhance computational efficiency and accuracy, crucial for early diagnosis and treatment planning [89].

In diagnosis

- Diagnostic accuracy: AI methods have shown high diagnostic accuracy, with area under curve values ranging from 0.80 to 0.96. Convolutional neural networks have been particularly effective, demonstrating high sensitivity and specificity in various studies.

- Biomarker detection: AI has facilitated the non-invasive detection of biomarkers, such as circulating tumor cells and microRNAs, which are promising for early breast cancer diagnosis. These biomarkers can potentially overcome the limitations of traditional screening methods [90].

In treatment

- Personalized medicine: AI's predictive capabilities aid in risk stratification and treatment response, particularly in managing triple-negative breast cancer. This allows for more personalized treatment plans, reducing recurrence and minimizing side effects [88].

- Clinical decision support: AI tools are used as clinical decision support systems, augmenting treatment decisions and improving workflow efficiency in multidisciplinary tumor board settings [88].

Limitations

- Data quality and algorithm transparency: Persistent challenges in AI adoption include data quality, algorithm transparency, and resource disparities. Addressing these issues is crucial for advancing AI applications in breast cancer care [88].

- Integration and scalability: Future advancements may focus on integrating multi-modal imaging and improving predictive capacities, which could enhance the reliability and scalability of AI systems in clinical practice [91].

While AI offers significant potential in improving breast cancer care, it is essential to consider the ethical concerns and real-world validation of these technologies. Ensuring the reproducibility of results and standardizing approaches will be critical for the safe and effective application of AI in medical practice. Additionally, the integration of explainable AI techniques can enhance model transparency and clinical trust, making AI tools more interpretable and reliable for clinicians [92].

In cervical cancer

AI is increasingly recognized as a transformative tool in the detection, diagnosis, and treatment of cervical cancer. By leveraging machine learning and deep learning algorithms, AI enhances the precision and efficiency of cervical cancer screening and management, particularly in resource-limited settings. This integration of AI into cervical cancer care aims to improve early detection, optimize diagnostic accuracy, and personalize treatment strategies, ultimately leading to better patient outcomes. The following sections explore the various applications and benefits of AI in cervical cancer care.

In detection

- Early detection and screening: AI technologies, such as deep learning models, have been employed to improve the accuracy of cervical cancer screening. For instance, the use of U-NET++ and RepVGG networks has shown high predictive accuracy in colposcopic image analysis, achieving an 83.01% accuracy rate in detecting early-stage lesions like CIN I and CIN II, which are crucial for timely intervention [93].

- Machine learning algorithms: Various machine learning algorithms, including logistic regression, support vector machines, and artificial neural networks, have been used to predict cervical cancer risk based on demographic and clinical attributes. Among these, artificial neural networks demonstrated the highest accuracy, achieving a score of 0.95 [94].

In diagnosis

- Image analysis and classification: AI-driven tools have been developed to enhance the diagnostic accuracy of cervical cancer by analyzing medical images. Convolutional neural networks and support vector machines have been used to classify cervical cells with high precision, reducing reliance on human interpretation and minimizing variability [95, 96].

- Integration with existing protocols: AI can be integrated into current diagnostic protocols to standardize screening procedures and improve the identification of early lesions. This integration helps in heightening the diagnostic accuracy of targeted biopsies and prognostic analysis [97].

In treatment

- Personalized treatment strategies: AI has the potential to move beyond diagnosis to perform risk analyses of HPV-related disease progression. By evaluating clinical elements such as vaccines and immune status, AI can generate risk scores to better stratify patients and support clinicians in choosing personalized treatments [97].

- Screen-and-treat approaches: AI tools, such as the visual inspection with acetic acid application (VIA)-AI algorithm, have been developed to guide treatment decisions in screen-and-treat programs. These tools help minimize overtreatment by accurately identifying and categorizing VIA-screen-positive areas for eligibility and suitability for ablative treatment. This pilot study develops and validates a VIA-AI tool using cervical images to reduce overtreatment in cervical cancer screening in South India, achieving 76% clinical accuracy and 20% false positive rate [98].

AI's role in cervical cancer care is not without challenges. The implementation of AI technologies requires addressing issues such as data privacy, model explainability, and the need for diverse datasets to develop versatile models. Additionally, the deployment of AI in low-resource settings necessitates overcoming infrastructural and logistical barriers. Despite these challenges, AI holds significant promise in enhancing cervical cancer care, particularly in underserved regions where traditional diagnostic infrastructure is lacking [99, 100].

Broader impact on cancer care

- Early detection and risk prediction: AI models predict cancer risk and facilitate early detection, which is crucial for improving survival rates. These models analyze large datasets to identify patterns and risk factors associated with cancer development [101, 102].

- Personalized treatment: AI supports the development of personalized treatment plans by integrating clinical, genomic, and imaging data. This approach minimizes side effects and enhances treatment efficacy compared to generalized therapies [101].

- Additionally, the accessibility and usability of AI tools for healthcare professionals in diverse settings are critical for maximizing their impact. Despite these challenges, AI continues to hold promises for revolutionizing cancer care by improving diagnostic accuracy and enabling personalized treatment strategies.

AI: Bias and Limitations

AI-based cancer diagnosis and treatment strategies hold significant promise for improving patient outcomes through enhanced precision and efficiency. However, these technologies are not without their biases and limitations, which can impact their effectiveness and equity in healthcare delivery (Table 4). Biases in AI models can arise from various sources, including data representation, algorithm design, and human oversight, potentially exacerbating existing health disparities. Understanding these biases and limitations is crucial for developing more equitable AI systems in oncology.

Sources of bias in AI models

- Data representation bias: AI models often reflect the biases present in the datasets they are trained on. For instance, underrepresentation of certain demographic groups, such as patients with darker skin tones, can lead to discrepancies in diagnostic accuracy, as seen in skin cancer classification models [103]. Similarly, biases related to patient demographics, such as age, have been observed in lung cancer treatment models, where accuracy varied between different age groups [104].

Table 4: Overview of bias and limitations of AI in cancer diagnosis and treatment.

Aspect	Bias and limitations
Data bias	• AI systems can be biased if trained on unrepresentative or non-diverse datasets, leading to inaccurate predictions for certain populations (e.g., ethnic groups and gender) • Underrepresentation of minority groups in medical data can cause AI models to perform poorly for these populations
Generalization	• AI models may struggle to generalize across different populations, geographical regions, or healthcare settings • A model trained in one country may not be as effective when applied to another due to differences in genetic profiles, healthcare infrastructure, or clinical practices
Interpretability	• Many AI models, especially deep learning models, act as "black boxes," making it difficult to understand how decisions are made, which reduces trust among clinicians and patients • Lack of transparency in AI's decision-making process can hinder clinical acceptance and the ability to identify potential errors
Overfitting	• AI models trained on limited or incomplete data can overfit, meaning they perform well on the training data but poorly on unseen real-world data
Regulatory and ethical concerns	• AI tools face challenges with regulatory approval, as the process is complex and time-consuming, especially for applications in critical healthcare decisions • Ethical concerns arise around the use of AI in cancer treatment, such as patient privacy, consent, and the role of AI in making life-altering decisions
Bias in historical data	• AI models that rely on historical medical data may inherit biases from past clinical practices, potentially reinforcing existing healthcare disparities
Model validation and reliability	• AI systems may require rigorous and extensive validation to ensure accuracy across different clinical environments and populations, which can be resource-intensive
Lack of training in clinical context	• AI may lack the nuanced understanding that experienced clinicians bring, especially in complex or rare cases where the AI model may not be sufficiently trained
Integration into clinical workflow	• The integration of AI into existing healthcare systems and workflows may be difficult, with challenges in clinician training, system compatibility, and ensuring AI tools are used effectively
Dependence on quality of data	• AI's effectiveness is heavily dependent on the quality of data available for training, and poor-quality data can lead to inaccurate or unreliable predictions
Cost and resource constraints	• Developing, implementing, and maintaining AI systems can be costly and resource-intensive, limiting access to high-quality AI tools in resource-poor settings

- Algorithmic bias: The design and implementation of AI algorithms can introduce biases. For example, AI models may inadvertently prioritize certain disease classifications over others, as demonstrated in lung cancer research where treatment predictions were more accurate for SCC compared to adenocarcinoma [104]. Additionally, biases can be introduced during the algorithm training phase if diverse data is not adequately incorporated [105].

- Human-AI interaction bias: Automation bias occurs when healthcare professionals overly rely on AI recommendations, potentially leading to incorrect clinical decisions. This bias can be exacerbated under time pressure, as seen in computational pathology, where practitioners were more likely to follow erroneous AI advice [106].

Limitations in AI deployment

- Transparency and explainability: A significant limitation in AI deployment is the lack of transparency and explainability in AI models. Many studies fail to provide access to their data or adequately report their methodologies, hindering reproducibility and trust in AI systems [107]. This lack of transparency can also impede the integration of AI into clinical workflows, as clinicians may be reluctant to adopt tools they do not fully understand [108].

- Regulatory and ethical challenges: The integration of AI into oncology faces regulatory hurdles, particularly concerning data privacy and security. Ensuring compliance with international guidelines and ethical standards is essential for the safe deployment of AI technologies [109]. Moreover, ethical concerns arise when AI models perpetuate biases, potentially worsening health disparities [105].

- Technical challenges: The complexity and multidimensionality of medical data pose technical challenges in developing AI solutions that generalize across diverse populations. The need for robust validation and testing of AI models in real-world settings is critical to ensure their reliability and effectiveness [105].

Mitigation strategies

To address these biases and limitations, several strategies have been proposed. Enhancing data diversity and representation through augmentation techniques can help mitigate biases in AI models [103]. Developing software tools to detect and correct biases, making AI models open access, and involving ethics review boards can further promote fairness and accountability [104]. Additionally, fostering transparency and explainability in AI systems is crucial for building trust and facilitating their integration into clinical practice [108].

While AI-based cancer diagnosis and treatment strategies offer transformative potential, they also present challenges that must be addressed to ensure equitable and effective healthcare delivery. By acknowledging and mitigating biases, enhancing transparency, and adhering to ethical standards, the oncology field can harness the full potential of AI technologies.

Limitations and Future Scope

Addressing breast and cervical cancers in Asian women requires tailored approaches that consider genetic predispositions, environmental factors, and cultural sensitivities. Genetic studies have identified specific mutations and polymorphisms that may increase cancer risk in Asian populations, highlighting the need for targeted genetic screening and counseling programs. Environmental factors, such as exposure to pollutants and occupational hazards, also need to be considered in cancer prevention strategies. To improve prevention, early detection, and treatment outcomes for Asian women, a multifaceted approach is necessary. This may include:

1. Developing culturally sensitive education and awareness programs to increase knowledge about cancer risk factors, prevention methods, and the importance of regular screening.

2. Implementing targeted screening guidelines that account for the earlier onset of breast cancer in Asian women and the specific risk factors prevalent in Asian populations.

3. Expanding access to HPV vaccination and cervical cancer screening services, particularly in rural and underserved areas.

4. Training healthcare providers to be culturally competent and sensitive to the unique needs and concerns of Asian women.

5. Investing in research to better understand the genetic and molecular characteristics of cancers in Asian populations, leading to more effective and personalized treatment approaches.

6. Addressing socioeconomic barriers to healthcare access and developing policies to ensure that all women have access to necessary preventive care and cancer treatments.

7. Collaborating with community leaders and organizations to overcome cultural barriers and promote health-seeking behaviors.

By addressing these challenges and implementing targeted interventions, it is possible to significantly reduce the burden of breast and cervical cancers among Asian women. This approach not only has the potential to improve health outcomes but also to enhance the overall quality of life for millions of women across Asia.

Conclusion

The review highlights the unique challenges associated with breast and cervical cancer among Asian women, emphasizing epidemiological trends, cultural barriers, and disparities in screening and treatment. The increasing incidence of breast cancer and the persistent burden of cervical cancer underscore the need for targeted interventions. Advancements in AI-assisted diagnostics and treatment strategies hold promise, but challenges such as healthcare accessibility, cultural stigma, and socioeconomic barriers remain. Addressing these issues requires a comprehensive approach that integrates technology with culturally sensitive healthcare policies.

Looking ahead, future research should focus on the genetic and molecular characteristics of these cancers in Asian populations. Large-scale genomic studies could provide deeper insights into risk factors, allowing for more precise, population-specific screening and treatment protocols. The role of AI should also be further explored, particularly in low-resource settings where automated screening tools could significantly improve early detection. Additionally, community-based interventions leveraging digital health technologies may bridge existing gaps in awareness and healthcare access, empowering women to seek timely medical care.

Policy and healthcare infrastructure must also evolve to address the growing cancer burden in Asia. Strengthening HPV vaccination programs, ensuring equitable access to breast cancer screening, and improving cancer treatment facilities are critical steps. Multidisciplinary collaborations between researchers, healthcare professionals, and policymakers can drive meaningful progress. By integrating scientific advancements with culturally tailored healthcare solutions, the long-term goal of reducing cancer-related mortality among Asian women can be effectively achieved.

Acknowledgements

None.

Conflict of Interest

None.

References

1. Chawla N, Breen N, Liu B, Lee R, Kagawa-Singer M (2015) Asian American women in California: a pooled analysis of predictors for breast and cervical cancer screening. Am J Public Health 105: e98–e109. https://doi.org/10.2105/ajph.2014.302250

2. Gupta A, Kumar A, Stewart DE (2002) Cervical cancer screening among South Asian women in Canada: the role of education and acculturation. Health Care Women Int 23: 123–134. https://doi.org/10.1080/073993302753429004

3. Ho IK, Dinh KT (2011) Cervical cancer screening among Southeast Asian American women. J Immigr Minor Health 13: 49–60. https://doi.org/10.1007/s10903-010-9358-0

4. Nayyar S, Chakole S, Taksande AB, Prasad R, Munjewar PK, et al. (2023) From awareness to action: a review of efforts to reduce disparities in breast cancer screening. Cureus 15: e40674. https://doi.org/10.7759/cureus.40674

5. Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, et al. (2020) European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nat Commun 11: 1-11. https://doi.org/10.1038/s41467-020-17680-w

6. Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6: 1–11. https://doi.org/10.1186/bcr932

7. Marino P, Mininni M, Deiana G, Marino G, Divella R, et al. (2024) Healthy lifestyle and cancer risk: modifiable risk factors to prevent cancer. Nutrients 16: 800. https://doi.org/10.3390/nu16060800

8. Seiler A, Chen MA, Brown RL, Fagundes CP (2018) Obesity, dietary factors, nutrition, and breast cancer risk. Curr Breast Cancer Rep 10: 14–27. https://doi.org/10.1007/s12609-018-0264-0

9. Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, et al. (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127: 471–478. https://doi.org/10.1007/s10549-010-1173-8

10. Siddharth S, Sharma D (2018) Racial disparity and triple-negative breast cancer in African-American women: a multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers 10: 514. https://doi.org/10.3390/cancers10120514

11. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A (2019) Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination—review of current perspectives. J Oncol 2019: 3257939. https://doi.org/10.1155/2019/3257939

12. Kombe AJK, Li B, Zahid A, Mengist HM, Bounda GA, et al. (2021) Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health 8: 1-19. https://doi.org/10.3389/fpubh.2020.552028

13. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, et al. (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8: e191–e203. https://doi.org/10.1016/s2214-109x(19)30482-6

14. Rathod S, Potdar J, Gupta A, Sethi N, Dande A, et al. (2023) Empowering women's Health: insights Into HPV vaccination and the prevention of invasive cervical cancer. Cureus 15: e49523. https://doi.org/10.7759/cureus.49523

15. Alshammari AH, Ishii H, Hirotsu T, Hatakeyama H, Morishita M, et al. (2024) Bridging the gap in cervical cancer screening for underserved communities: MCED and the promise of future technologies. Front Oncol 14: 1-10. https://doi.org/10.3389/fonc.2024.1407008

16. Carlos RC, Dempsey AF, Patel DA, Dalton VK (2010) Cervical cancer prevention through human papillomavirus vaccination: using the "teachable moment" for educational interventions. Obstet Gynecol 115: 834–838. https://doi.org/10.1097/aog.0b013e3181d502d7

17. Zhetpisbayeva I, Kassymbekova F, Sarmuldayeva S, Semenova Y, Glushkova N (2023) Cervical cancer prevention in rural areas. Ann Glob Health 89: 1-15. https://doi.org/10.5334/aogh.4133

18. Rashidian M, Minichiello V, Knutsen S, Ghamsary M (2020) Western, Asian, and middle eastern societies' cultural attitudes and barriers impacting the management of sexual health care. In Rowland D, Jannini E (eds) Cultural Differences and the Practice of Sexual Medicine. Springer, pp 165–182.

19. Kreps GL, Sparks L (2008) Meeting the health literacy needs of immigrant populations. Patient Educ Couns 71: 328–332. https://doi.org/10.1016/j.pec.2008.03.001

20. Shim JK (2010) Cultural health capital: a theoretical approach to understanding health care interactions and the dynamics of unequal treatment. J Health Soc Behav 51: 1–15. https://doi.org/10.1177/0022146509361185

21. Castle PE, Einstein MH, Sahasrabuddhe VV (2021) Cervical cancer prevention and control in women living with human immunodeficiency virus. CA Cancer J Clin 71: 505–526. https://doi.org/10.3322/caac.21696

22. Lu M, Moritz S, Lorenzetti D, Sykes L, Straus S, et al. (2012) A systematic review of interventions to increase breast and cervical cancer screening uptake among Asian women. BMC Public Health 12: 1-16. https://doi.org/10.1186/1471-2458-12-413

23. Afaya A, Ramazanu S, Bolarinwa OA, Yakong VN, Afaya RA, et al. (2022) Health system barriers influencing timely breast cancer diagnosis and treatment among women in low and middle-income Asian countries: evidence from a mixed-methods systematic review. BMC Health Serv Res 22: 1-17. https://doi.org/10.1186/s12913-022-08927-x

24. Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, et al. (2019) Insights into breast cancer in the east vs the west: a review. JAMA Oncol 5: 1489–1496. https://doi.org/10.1001/jamaoncol.2019.0620

25. Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY (2021) Disparities in cancer care and the Asian American population. Oncologist 26: 453–460. https://doi.org/10.1002/onco.13748

26. Wang SS, Carreon JD, Gomez SL, Devesa SS (2010) Cervical cancer incidence among 6 Asian ethnic groups in the United States, 1996 through 2004. Cancer 116: 949–956. https://doi.org/10.1002/cncr.24843

27. Bae JM, Kim EH (2016) Breast density and risk of breast cancer in Asian women: a meta-analysis of observational studies. J Prev Med Public Health 49: 367-375. https://doi.org/10.3961/jpmph.16.054

28. Satagopan JM, Stroup A, Kinney AY, Dharamdasani T, Ganesan S, et al. (2021) Breast cancer among Asian Indian and Pakistani Americans: a surveillance, epidemiology and end results-based study. Int J Cancer 148: 1598–1607. https://doi.org/10.1002/ijc.33331

29. Yu AYL, Thomas SM, DiLalla GD, Greenup RA, Hwang ES, et al. (2022) Disease characteristics and mortality among Asian women with breast cancer. Cancer 128: 1024–1037. https://doi.org/10.1002/cncr.34015

30. Wang H, MacInnis RJ, Li S (2023) Family history and breast cancer risk for Asian women: a systematic review and meta-analysis. BMC Med 21: 1-13. https://doi.org/10.1186/s12916-023-02950-3

31. Chehade R, Juni Y, Zhu JW, Tavanger F, Jerzak KJ, et al. (2024) Exploring differences in breast cancer presentation, recurrence and survival by race/ethnicity among young women in the prospective PYNK database. J Young Womens Breast Cancer Health 1: 51–57. https://doi.org/10.4103/ywbc.ywbc_16_24

32. Gondhowiardjo S, Christina N, Ganapati NP, Hawariy S, Radityamurti F, et al. (2021) Five-year cancer epidemiology at the national referral hospital: hospital-based registry data in Indonesia. JCO Glob Oncol 5: 190–203. https://doi.org/10.1200/go.20.00155

33. Monk BJ, Tan DS, Chagüi JDH, Takyar J, Paskow MJ, et al. (2022) Proportions and incidence of locally advanced cervical cancer: a global systematic literature review. Int J Gynecol Cancer 32: 1531–1539. https://doi.org/10.1136/ijgc-2022-003801

34. Moodley J, Constant D, Mwaka AD, Scott SE, Walter FM (2020) Mapping awareness of breast and cervical cancer risk factors, symptoms and lay beliefs in Uganda and South Africa. PLoS One 15: e0240788. https://doi.org/10.1371/journal.pone.0240788

35. Eslahi M, Roshandel G, Torkian S (2022) Trends in the incidence rates of breast and gynecological cancers in Asia from 1998-2012: an ecological study. Arch Iran Med 25: 112–117. https://doi.org/10.34172/aim.2022.18

36. Katanoda K, Ito Y, Sobue T (2021) International comparison of trends in cancer mortality: Japan has fallen behind in screening-related cancers. Jpn J Clin Oncol 51: 1680–1686. https://doi.org/10.1093/jjco/hyab139

37. Moodley J, Constant D, Mwaka AD, Scott SE, Walter FM (2021) Anticipated help seeking behaviour and barriers to seeking care for possible breast and cervical cancer symptoms in Uganda and South Africa. ecancermedicalscience 15: 1171. https://doi.org/10.3332/ecancer.2021.1171

38. Xie Z, Chen G, Suk R, Dixon B, Jo A, et al. (2023) Limited English proficiency and screening for cervical, breast, and colorectal cancers among Asian American adults. J Racial Ethn Health Disparities 10: 977–985. https://doi.org/10.1007/s40615-022-01285-8

39. Kagawa-Singer M, Pourat N, Breen N, Coughlin S, Abend McLean T, et al. (2007) Breast and cervical cancer screening rates of subgroups of Asian American women in California. Med Care Res Rev 64: 706–730. https://doi.org/10.1177/1077558707304638

40. Wang JH, Sheppard VB, Schwartz MD, Liang W, Mandelblatt JS (2008) Disparities in cervical cancer screening between Asian American and Non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 17: 1968–1973.

41. Wen KY, Fang CY, Ma GX (2014) Breast cancer experience and survivorship among Asian Americans: a systematic review. J Cancer Surviv 8: 94–107. https://doi.org/10.1007/s11764-013-0320-8

42. Lee HY, Ju E, Vang PD, Lundquist M (2010) Breast and cervical cancer screening disparity among Asian American women: does race/ethnicity matter? J Womens Health 19: 1877–1884. https://doi.org/10.1089/jwh.2009.1783

43. Wu TY, Bancroft J, Guthrie B (2005) An integrative review on breast cancer screening practice and correlates among Chinese, Korean, Filipino, and Asian Indian American women. Health Care Women Int 26: 225–246. https://doi.org/10.1080/07399330590917780

44. Liu D, Schuchard H, Burston B, Yamashita T, Albert S (2021) Interventions to reduce healthcare disparities in cancer screening among minority adults: a systematic review. J Racial Ethn Health Disparities 8: 107–126. https://doi.org/10.1007/s40615-020-00763-1

45. Cullerton K, Gallegos D, Ashley E, Do H, Voloschenko A, et al. (2016) Cancer screening education: can it change knowledge and attitudes among culturally and linguistically diverse communities in Queensland, Australia? Health Promot J Aust 27: 140–147. https://doi.org/10.1071/he15116

46. Nguyen TU, Tanjasiri SP, Kagawa-Singer M, Tran JH, Foo MA (2008) Community health navigators for breast- and cervical-cancer screening among Cambodian and Laotian women: intervention strategies and relationship-building processes. Health Promot Pract 9: 356–367. https://doi.org/10.1177/1524839906290251

47. So WK, Kwong AN, Chen JM, Chan JC, Law BM, et al. (2019) A theory-based and culturally aligned training program on breast and cervical cancer prevention for South Asian community health workers: a feasibility study. Cancer Nurs 42: E20–E30. https://doi.org/10.1097/ncc.0000000000000543

48. Percac-Lima S, Grant RW, Green AR, Ashburner JM, Gamba G, et al. (2009) A culturally tailored navigator program for colorectal cancer screening in a community health center: a randomized, controlled trial. J Gen Intern Med 24: 211–217. https://doi.org/10.1007/s11606-008-0864-x

49. Lee HY, Lee MH, Gao Z, Sadak K (2018) Development and evaluation of culturally and linguistically tailored mobile app to promote breast cancer screening. J Clin Med 7: 181. https://doi.org/10.3390/jcm7080181

50. Glaser KM, Crabtree-Ide CR, McNulty AD, Attwood KM, Flores TF, et al. (2024) Improving guideline-recommended colorectal cancer screening in a federally qualified health center (FQHC): implementing a patient navigation and practice facilitation intervention to promote health equity. Int J Environ Res Public Health 21: 126. https://doi.org/10.3390/ijerph21020126

51. Kaur R, Bhardwaj A, Gupta S (2023) Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep 50: 9663–9676. https://doi.org/10.1007/s11033-023-08809-3

52. Mir MA, Mir AY (2023) Current treatment approaches to breast cancer. In Mir M (ed) Therapeutic Potential of Cell Cycle Kinases in Breast Cancer. Springer Nature, Singapore, pp 23–51.

53. Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, et al. (2022) Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res 13: 200238. https://doi.org/10.1016/j.tvr.2022.200238

54. Guimarães YM, Godoy LR, Longatto-Filho A, Reis RD (2022) Management of early-stage cervical cancer: a literature review. Cancers 14: 575. https://doi.org/10.3390/cancers14030575

55. Gharoonpour A, Simiyari D, Yousefzadeh A, Badragheh F, Rahmati M (2023) Autophagy modulation in breast cancer utilizing nanomaterials and nanoparticles. Front Oncol 13: 1-20. https://doi.org/10.3389/fonc.2023.1150492

56. Vlastos G, Verkooijen HM (2007) Minimally invasive approaches for diagnosis and treatment of early-stage breast cancer. Oncologist 12: 1–10. https://doi.org/10.1634/theoncologist.12-1-1

57. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K (2010) Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 1: 109–126.

58. Singh HV, Shahid M, Jain A, Singhai AK (2024) Breast cancer: from etiology to therapeutic interventions. Res J Pharmacol Pharmacodyn 16: 199–207. http://dx.doi.org/10.52711/2321-5836.2024.00034

59. Jha RK, Dhale HS (2024) Treatment on carcinoma of breast. In Case Studies on Holistic Medical Interventions. CRC Press, pp 665–668.

60. Singhai H, Raikwar S, Rathee S, Jain SK (2025) Emerging combinatorial drug delivery strategies for breast cancer: a comprehensive review. Curr Drug Targets 26: 331-349. https://doi.org/10.2174/0113894501352081241211090911

61. Jaishree S, Selvaraj K, Prakash S, Vineesh D (2024) Innovative nanoscale drug delivery strategies for breast carcinoma: a comprehensive exploration. Curr Drug Metab 25: 391–402. https://doi.org/10.2174/0113892002298034240802110752

62. Yang L, Hu Q, Huang T (2024) Breast cancer treatment strategies targeting the tumor microenvironment: how to convert “cold” tumors to “hot” tumors. Int J Mol Sci 25: 7208. https://doi.org/10.3390/ijms25137208

63. Zagardo V, Harikar M, Ferini G (2024) Therapeutic strategies for fungating and ulcerating breast cancers: a systematic review and narrative synthesis. Breast 79: 103870. https://doi.org/10.1016/j.breast.2024.103870

64. Liu Y (2024) Treatment and prevention strategies of breast cancer. Theor Natl Sci 63: 51–55. https://doi.org/10.54254/2753-8818/63/20241570

65. Zhou P, Liu W, Cheng Y, Qian D (2021) Nanoparticle-based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 13: e1718. https://doi.org/10.1002/wnan.1718

66. Wargantiwar S, Bhattacharya S, Kanugo A (2025) Surgical advancements, immunotherapy, targeted and conventional therapies, biopsy, colposcopy, and Pap smear integration in the management of cervical cancer. Curr Med Chem (In Press). https://doi.org/10.2174/0109298673337745241123054840

67. Salman L, Covens A (2024) Fertility preservation in cervical cancer-treatment strategies and indications. Curr Oncol 31: 296–306. https://doi.org/10.3390/curroncol31010019

68. Ambad RS, Malve RR (2024) Cervical cancer management: a comprehensive overview. In Case Studies on Holistic Medical Interventions. CRC Press, pp 600–603.

69. Singh AK, Sundram S, Arya H, Vandana, Malviya R (2024) Treatment strategies for cervical cancer in older women: challenges and advancements. Curr Cancer Ther Rev 20: 142–153. https://doi.org/10.2174/1573394719666230707145133

70. Ferrall L, Lin KY, Roden RB, Hung CF, Wu TC (2021) Cervical cancer immunotherapy: facts and hopes. Clin Cancer Res 27: 4953–4973.

71. Iwata T (2024) New therapeutic strategies for cervical cancer with special reference to immunotherapy. In Aoki D (ed) Recent Topics on Prevention, Diagnosis, and Clinical Management of Cervical Cancer. Comprehensive Gynecology and Obstetrics. Springer Nature, Singapore, pp 205–216.

72. Girda E, Randall LM, Chino F, Monk BJ, Farley JH, et al. (2023) Cervical cancer treatment update: a Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 179: 115–122. https://doi.org/10.1016/j.ygyno.2023.10.017

73. Saha I, Halder J, Rajwar TK, Mahanty R, Pradhan D, et al. (2024) Novel drug delivery approaches for the localized treatment of cervical cancer. AAPS PharmSciTech 25: 85. https://doi.org/10.1208/s12249-024-02801-1

74. Srinivasan G (2024) Cervical cancer: novel treatment strategies offer renewed optimism. Pathol Res Pract 254: 155136. https://doi.org/10.1016/j.prp.2024.155136

75. Olthof EP, Wenzel HH, van der Velden J, Stalpers LJ, Mom CH, et al. (2024) Treatment strategies guided by [18F]FDG-PET/CT in patients with locally advanced cervical cancer and [18F]FDG-positive lymph nodes. Cancers 16: 717. https://doi.org/10.3390/cancers16040717

76. Tan MP, Sitoh YY (2019) Are breast conservation treatment rates optimized for Asian women with symptomatic malignancies? ANZ J Surg 89: 529–535. https://doi.org/10.1111/ans.15084

77. Wong FY, Tham WY, Nei WL, Lim C, Miao H (2018) Age exerts a continuous effect in the outcomes of Asian breast cancer patients treated with breast-conserving therapy. Cancer Commun 38: 1–11. https://doi.org/10.1186/s40880-018-0310-3

78. Lee KWC, Lord S, Finn RS, Lim E, Martin A, et al. (2019) The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat 174: 271–278. https://doi.org/10.1007/s10549-018-5054-x

79. Kim SB, Sayeed A, Villalon AH, Shen ZZ, Shah MA, et al. (2016) Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: results from 5 years follow-up on Asia-Pacific Breast Initiative-I. Asia-Pac J Clin Oncol 12: 125–132. https://doi.org/10.1111/ajco.12454

80. Chan WL, Cheng MHF, Wu JTK, Choi CW, Tse RPY, et al. (2022) Treatment outcomes of computer tomography-guided brachytherapy in cervical cancer in Hong Kong: a retrospective review. Cancers 14: 3934. https://doi.org/10.3390/cancers14163934

81. Xiang Y, Hasegawa K, Zhu H, Zhou Q, Zhang X, Lee JY, et al. (2024) 23O a randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): results for patients enrolled in Asia. ESMO Open 9. https://doi.org/10.1016/j.esmoop.2024.103523

82. Liu J, Tang G, Zhou Q, Kuang W (2022) Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. Radiat Oncol 17: 1-11. https://doi.org/10.1186/s13014-022-02115-1

83. Tokarski AO, Bernardelli RS, Bruscato JR, Lucena CR, Linhares JC, Tsunoda AT (2024) Quality of life post cervical cancer treatment: a comparison between radical surgery approach and radiotherapy and chemotherapy. J Surg Oncol 130: 904–912. https://doi.org/10.1002/jso.27911

84. Zhang C, Xu J, Tang R, Yang J, Wang W, et al. (2023) Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment. J Hematol Oncol 16: 1-29. https://doi.org/10.1186/s13045-023-01514-5

85. Ahmed Z, Mohamed K, Zeeshan S, Dong X (2020) Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database 2020: baba010. https://doi.org/10.1093/database/baaa010

86. Asif S, Wenhui Y, ur-Rehman S, ul-ain Q, Amjad K, Yueyang Y, et al. (2024) Advancements and prospects of machine learning in medical diagnostics: unveiling the future of diagnostic precision. Arch Comput Methods Eng 32: 853–883. https://doi.org/10.1007/s11831-024-10148-w

87. Gui H, Jiao H, Li L, Jiang X, Su T, et al. (2024) Breast tumor detection and diagnosis using an improved Faster R-CNN in DCE-MRI. Bioengineering 11: 1217. https://doi.org/10.3390/bioengineering11121217

88. Uchikov P, Khalid U, Dedaj-Salad GH, Ghale D, Rajadurai H, et al. (2024) Artificial intelligence in breast cancer diagnosis and treatment: advances in imaging, pathology, and personalized care. Life 14: 1451. https://doi.org/10.3390/life14111451

89. Jain C, Srinet SS, Goyal TK, Karpagam M (2024) AI4Bcancer: breast cancer classification using AutoML-TPOT with PCA. In 2nd DMIHER International Conference on Artificial Intelligence in Healthcare, Education and Industry (IDICAIEI).

90. Humayun S, Mahmood T (2025) Artificial intelligence for early diagnosis of breast cancer in women: a systematic literature review. Artif Intell Health 2: 100-116. https://doi.org/10.36922/aih.4197

91. Garcia-Saiso S, Marti M, Pesce K, Luciani S, Mujica O, Hennis A, et al. (2024) Artificial intelligence as a potential catalyst to a more equitable cancer care. JMIR Cancer 10: 1-8. https://doi.org/10.2196/57276

92. Tanim SA, Alam GMI, Shrestha TE, Islam M, Jahan F, et al. (2024) Breast cancer diagnosis with XAI-integrated deep learning approach. In International Conference on Innovation and Intelligence for Informatics, Computing, and Technologies (3ICT).

93. Li B, Chen L, Sun C, Wang J, Ma S (2025) Leveraging deep learning for early detection of cervical cancer and dysplasia in China using U-NET++ and RepVGG networks. JMIR Preprints.

94. Verma S, Suthar H, Rami K (2024) Empowering early detection: cervicalcareXG revolutionizes cervical type cancer diagnostics. In 4th Asian Conference on Innovation in Technology (ASIANCON).

95. Priyadarsini S, Mareeswari A, Subhashini M, Gayathri N (2025) Diagnosis of utrine cervical cancer using deep learning. In Challenges in Information, Communication and Computing Technology. CRC Press, pp 305–309.

96. Shah PN, Khan RAH (2024) A review paper on innovative deep learning and machine learning algorithms for improved cervical cancer identification. In 4th International Conference on Sustainable Expert Systems (ICSES).

97. Dellino M, Cerbone M, d'Amati A, Bochicchio M, Laganà AS, et al. (2024) Artificial intelligence in cervical cancer screening: opportunities and challenges. AI 5: 2984–3000. https://doi.org/10.3390/ai5040144

98. Poli UR, Gudlavalleti AG, Bharadwaj YJ, Pant HB, Agiwal V, et al. (2024) Development and clinical validation of visual inspection with acetic acid application–artificial intelligence tool using cervical images in screen-and-treat visual screening for cervical cancer in South India: a pilot study. JCO Glob Oncol 10:e2400146. https://doi.org/10.1200/go.24.00146

99. Kolsanova AV, Chechko SM, Kira EF, Shamshatdinova AR (2024) Cervical screening and artificial intelligence. Sci Innov Med 9: 246–250. https://doi.org/10.35693/sim640828

100. Khare SK, Blanes-Vidal V, Booth BB, Petersen LK, Nadimi ES (2024) A systematic review and research recommendations on artificial intelligence for automated cervical cancer detection. WIREs Data Min Knowl Discov 14: e1550. https://doi.org/10.1002/widm.1550

101. Tousif MN, Akhter R, Ushan MNR, Labonno TM, Mahmud S, et al. (2023) Revolutionizing cancer therapy: the role of artificial intelligence in enhancing treatment efficacy. In International Conference on Information and Communication Technology for Sustainable Development (ICICT4SD).

102. Mathur S, Sharma AK, Yadav A (2023) Analysis of diagnostic value of cervical cancer disease through artificial intelligence based system. In Proceedings of the 5th International Conference on Information Management & Machine Intelligence.

103. Raizman E, Peng Y, Deng A (2024) Towards equitable diagnosis: bias evaluation and mitigation in skin cancer classification. In IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB).

104. Ding K, Forbes S, Ma F, Luo G, Zhou J, et al. (2024) AI bias in lung cancer radiotherapy. Explor Digit Health Technol 2: 302–312. https://doi.org/10.37349/edht.2024.00030

105. Corti C, Cobanaj M, Dee EC, Criscitiello C, Tolaney SM (2024) Artificial intelligence in cancer research and precision medicine: applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. Cancer Treat Rev 112: 102498. https://doi.org/10.1016/j.ctrv.2022.102498

106. Rosbach E, Ganz J, Ammeling J, Riener A, Aubreville M (2024) Automation bias in AI-assisted medical decision-making under time pressure in computational pathology. In Image Processing for Medicine 2025. BVM 2025. Computer Science Today. Springer Vieweg, Wiesbaden, pp 129–134.

107. Smiley A, Reategui-Rivera CM, Villarreal-Zegarra D, Escobar-Agreda S, Finkelstein J (2025) Exploring artificial intelligence biases in predictive models for cancer diagnosis. Cancers 17: 407. https://doi.org/10.3390/cancers17030407

108. Duwe G, Mercier D, Wiesmann C, Kauth V, Moench K, et al. (2024) Challenges and perspectives in use of artificial intelligence to support treatment recommendations in clinical oncology. Cancer Med 13: e7398. https://doi.org/10.1002/cam4.7398

109. Kolla L, Parikh RB (2024) Uses and limitations of artificial intelligence for oncology. Cancer 130: 2101–2107. https://doi.org/10.1002/cncr.35307